Alembic Pharmaceuticals Limited announced on Friday, June 27, 2025, the approval of an ANDA by the U.S. FDA for doxorubicin hydrochloride injection, a generic version of the oncology treatment, positioning the company to further leverage its diversified portfolio and capture a share of the generic chemotherapeutic market.